Progress toward development of an inhalation vaccine against botulinum toxin

Expert Review of Vaccines

Volumn 3, Issue 4, 2004, Pages 477-487

  Park, Jong Beak ^a   Simpson, Lance L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Botulinum toxin; Clostridium botulinum; Clostridium retani; Epithelial cell; Immunization; Inhalation; Tetanus toxin; Toxoid; Vaccine

Indexed keywords

BOTULINUM TOXIN; BOTULINUM VACCINE; CHOLERA TOXIN; PERTUSSIS TOXIN; POLYPEPTIDE; SUBUNIT VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

ADSORPTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; BIOLOGICAL WARFARE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; HUMANS; TETANUS TOXOID; VACCINES, SYNTHETIC;

EID: 4043119057     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.477     Document Type: Review

References (67)

1. Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog. Neurobiol. 46, 83-96 (1995).
2. Simpson LL. Identification of the major steps in botulinum toxin action. Ann. Rev. Pharmacol. Toxicol. 44, 167-193 (2004).
3. Arnon SS. Infant botulism. Ann. Rev. Med. 31, 541-560 (1980).
4. Wigginton JM, Thill P. Infant botulism. Clin. Pediatr. 32, 669-674 (1993).
5. Midura TF. Update: infant botulism. Clin. Microbiol. Rev. 9, 119-125 (1996).
6. China JK, Clark JB, Ryan CA. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N. Engl. J. Med. 315, 239-241 (1986).
7. Minton NP. Molecular genetics of clostridial neurotoxins. Curr. Top. Microbiol. Immunol. 195, 161-194 (1995).
8. Oguma K, Fujinaga Y, Inoue K. Structure and function of Clostridium botulinum toxins. Microbiol. Immunol. 39, 161-168 (1995).
9. Lacy BD, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291, 1091-1104 (1999).
10. Popoff MR, Marvaud J-C. Structural and genomic features of clostridial neurotoxins. In: Comprehensive Sourcebook of Bacterial Protein Toxins. Alouf JE, Freer JH (Eds). Academic Press, London, UK, 174-201 (1999).
11. Maksymowych AB, Simpson LL. Binding and transcytosis of botulinum toxin at polarized human colon carcinoma cells. J. Biol. Chem. 273, 21950-21957 (1998).
12. Herreros J, Lalli G, Montecucco C, Schiavo G. Pathophysiological properties of clostridial neurotoxins. In: Comprehensive Sourcebook of Bacterial Protein Toxins. Alouf JE, Freer JH (Eds). Academic, London, UK, 202-228 (1999).
13. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82, 427-446 (2000).
14. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766 (2000).
15. Simpson LL. Identification of the characterics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie 82, 943-953 (2000).
16. Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog. Neurobiol. 46, 83-96 (1995).
17. Dong M, Richards DA, Goodnough MC et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162(7), 1293-1303 (2003).
18. Galazka A, Gasse F. The present status of tetanus and tetanus vaccination. Curr. Top. Microbiol. Immunol. 195, 31-53 (1995).
19. Curtis DP, De Groat WC. Tetanus toxin and spinal inhibition. Brain Res. 10, 208-212 (1968).
20. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos. R. Soc. Lond. B. Biol. Sci. 354, 259-268 (1999).
21. Sutton JM, Chow-Worn O, Spaven L et al. Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurones. FEBS Lett. 493(1), 45-49(2001).
22. Fotinou C, Emsley P, Black I et al. The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J. Biol. Chem. 276(34), 32274-3281 (2001).
23. Corradin G, Watts C. Cellular immunology of tetanus toxoid. Curr. Top. Microbiol. Immunol. 195, 77-87 (1995).
24. Makoff AJ, Ballantine SP, Smallwood AE, Fairweather NF. Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine. Biol. Tech. 7, 1043-1046 (1989).
25. Figueiredo D, Turcotte C, Frankel G et al. Characterization of recombinant tetanus toxin derivatives suitable for vaccine development. Infect. Immun. 63(8), 3218-3221 (1995).
26. Romanos MA, Makoff AJ, Fairweather NF et al. Expression of tetanus toxin fragment C in yeast: gene synthesis is required in eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res. 19, 1461-1467 (1991).
27. Charles IG, Rodgers BC, Makoff AJ et al. Synthesis of TeNT fragment C in insect cells by use of a baculovirus expression system. Infect. Immun. 59, 1627-1632 (1991).
28. Fiock MA, Cardella MA, Gearinger NF. Studies on immunity to toxins of Clostridium botulinum. Immunologic response of man to purified pentavalent ABCDE toxoid. J. Immunol. 90, 697-702 (1963).
29. Siegel LS. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 26(11), 2351-2356 (1988).
30. Ellis RJ. Immunobiologic agents and drugs available from the Centers for Disease Control and Prevention. Descriptions, recommendations, adverse reactions and serological response. Centers for Disease Control and Prevention (1982).
31. Hatheway CL. Immunogenecity of the neurotoxins of Clostridium botulinum. In: Therapy with botulinum toxin. Jankovic J, Hallett M (Eds), Marcel Dekker, NY, USA, 93-107 (1994).
32. Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in E. coli. Infect. Immun. 63(7), 2738-2742 (1995).
33. LaPenotiere HF, Clayton MA, Middlebrook JL. Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon 33(10), 1383-1386 (1995).
34. Bryne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency and efficacy of the botulinum neurotoxin type A binding domain from Pichiapastoris as a recombinant vaccine candidate. Infect. Immun. 66(10), 4817-4822 (1998).
35. Smith LA. Development of recombinant vaccine for botulinum neurotoxin. Toxicon 36(11), 1539-1548 (1998).
36. Clayton J, Middlebrook JL. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 18, 1855-1862 (2000).
37. Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 21, 3110-3117 (2003).
38. Yamashiroya HM, Ehrlich R, Magis JM. Aerosol vaccination with tetanus toxoid. Bacteriol. Rev. 30(3), 624-635 (1966).
39. Wigley FM, Wood SH, Waldman RH. Aerosol immunization of humans with tetanus toxoid. J. Immunol. 103(5), 1096-1098 (1969).
40. Bartlema HC, Braunius R, Hölscher L. Studies on respiratory immunization with tetanus toxoid: the role of adjuvants. J. Hyg. 70, 627-638 (1972).
41. Jung T, Kamm W, Breitenbach A et al. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 18(3), 352-360 (2001).
42. Westerink MAJ, Smithson SL, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ. Projuvant™ (pluronic F127®/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20, 711-723 (2002).
43. Simecka JW, Jackson RJ, Kiyono H, McGhee JR. Mucosally induced immunoglobin E-associated inflammation in the respiratory tract. Infect. Immun. 68(2), 672-679 (2000).
44. McCluskie MJ, Davis HL. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19, 413-422 (2001).
45. Eastcott JW, Holmberg CJ, Dewhirst FE et al. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19, 1636-1642 (2001).
46. Fairweather NF, Lyness VA, Maskell DJ. Immunization of mice against tetanus with fragment of tetanus toxin synthesized in E. coli. Infect. Immun. 55(11), 2541-2545 (1987).
47. Yasuda Y, Isaka M, Taniguchi T et al. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum land mucosal immune responses in the presence of anti-rCTB antibodies. Vaccine 21(21-22), 2954-2963 (2003).
48. Kweon MN, Yamamoto M, Watanabe F et al. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J. Infect. Dis. 186, 1261-1269 (2002).
49. Barry EM, Gomez-Duarte O, Chatfield S et al. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect. Immun. 64(10), 4172-4180 (1996).
50. Galen JE, Gomez-Duarte OG, Losonsky GA et al. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15(6-7), 700-708 (1997).
51. Norton PM, Wells JM, Brown HWG, Macpherson AM, Le Page RWF. Protection against tetanus toxin in mice nasally immunized with recombinant Lactobacillus lactis expressing tetanus toxin fragment C. Vaccine 15(6-7), 616-619 (1997).
52. Medaglini D, Ciabattini A, Spinosa MR et al. Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice. Vaccine 19, 1931-1939 (2001).
53. Grangette C, Muller-Alouf H, Goudercourt D et al. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69(3), 1547-1553 (2001).
54. Reveneau N, Geoffroy M-C, Locht C, Chagnaud P, Mercenier A. Comparison of the immune responses induced by local immunization with recombinant Lactobacillus plantarum tetanus toxin fragment C in different cellular locations. Vaccine 20(5-6), 1769-1777 (2002).
55. Reveneau N, Alonso S, Jacob-Dubuisson F, Mercenier A, Locht C. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis. Vaccine 20, 926-933 (2001).
56. Stevenson A, Roberts M. Use of a rationally attenuated Bordetella bronchisepta as a live mucosal vaccine and vector for heterologous antigens. Vaccine 20(17-18), 2325-2335 (2002).
57. Shi Z, Zeng M, Yang G et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75 (23), 11474-11482 (2001).
58. Duc LH, Hong HA, Fairweather N, Ricca E, Cutting SM. Bacterial spores as vaccine vehicles. Infect. Immun. 71(5), 2810-2818 (2003).
59. Maksymowych AB, Reinhard M, Malizio CJ et al. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 67, 4708-4712 (1999).
60. Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 39, 1703-1722 (2001).
61. Holzer VE. Botulisimus durch inhalation. Med. Klin. 57, 1735-1738 (1962).
62. Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. J. Am. Med. Ass. 285, 1059-1070 (2001).
63. Franz DR, Jahring PB, Friedlander AM et al. Clinical recognition and management of patients exposed to biological warfare agents. J. Am. Med. Ass. 278(5), 399-411 (1997).
64. Atlas RM. Bioterrorism: from threat to reality. Ann. Rev. Microbiol. 56, 167-185 (2002).
65. Park J-B, Simpson LL. Inhalation poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infla. Immun. 71(3), 1147-1154 (2003).
66. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 324, 1186-1194 (1991).
67. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 56, 80-99 (1992).